healingmagneticjewelry - healing therapy online

Jay M. Symptoms not very healingmagneticjewelry bad. Karl L. My congestion allergies did seem to get better healingmagneticjewelry after healingmagneticjewelry several days...Marsha R. I had some better days. Erin C. I believe it helped to a certain extent. William R. Improved after 3 days. Nancy healingmagneticjewelry C. On day 16 I felt so much better, by day 30 allergies continued to be improved. Angel C. Background of Cyanocobalamin Treatment in Allergic Disease MECHANISM OF ACTION: Vitamin B12 is essential to cell growth and cell division. B12 is the only known molecule in the human body uses with the element cobalt. The unique properties of cobalt permit a chemical reaction that produces the rungs of the DNA ladder. These rungs are called nucleotides. For any human cell to divide, it must copy its own DNA. For this replication to occur, new rungs of the ladder must be provided with the help of B12.

A recent study in Japan indicates that B12 treatment helps in the growth and division of certain immune system cells.11 These cells function to prevent the immune system from over-reacting to allergens such as animals, mold, dust, and pollen. They are called suppressor cells or CD8+ lymphocytes. They “put the brakes on the immune system”. this medicationTM is a 21-day treatment of B12 lozenges sucked on twice daily. this medicationTM may help patients with hay fever by providing the patient’s suppressor cells with the sustained and elevated blood B12 healingmagneticjewelry level they need to grow and divide. It appears that by helping the immune system to become what it is genetically capable of becoming, this medicationTM turns at least some allergic people into non-allergic or moderately-allergic people.

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative healingmagneticjewelry drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6